Pathos raises $237 million in Bristol Myers-led Series E at $3 billion valuation
Pathos raised $237 million in a Bristol Myers Squibb-led Series E, lifting its valuation to $3 billion as it expands AI drug development into Alzheimer’s.
This section contains the website’s posts.